US Obesity Rates Decline Amid Surge in GLP-1 Drug Use
For the first time in over a decade, the adult obesity rate in the United States has shown a statistically significant decline, dropping from 39.9% in 2022 to 37.0% in 2025, according to new data from Gallup’s National Health and Well-Being Index. This reduction represents approximately 7.6 million fewer adults classified as obese in just three years. The decline coincides with a sharp increase in the use of GLP-1 receptor agonist medications, such as semaglutide (brands Ozempic and Wegovy), which have been prescribed specifically for weight loss since early 2024.
Study Findings
The Gallup survey, based on responses from 16,946 US adults during the first three quarters of 2025, found that the proportion of adults using GLP-1 injections for weight loss doubled from 5.8% in February 2024 to 12.4% by late 2025. The increase was more pronounced among women (15.2%) than men (9.7%), and obesity rates dropped more sharply among women (down 3.5 percentage points) than men (down 2.3 points) since 2022. The most notable declines were seen in adults aged 40–49 and 50–64, groups with the highest rates of GLP-1 use. However, seniors, despite having the third-highest usage rate (11.1%), did not show a corresponding reduction in obesity, likely due to lower reported effectiveness of these medications in older age groups.
Public Health Implications
The data reveal a clear correlation between GLP-1 drug use and reduced obesity rates, particularly among middle-aged adults. However, the percentage of Americans diagnosed with diabetes has reached 13.8%, the highest ever recorded in Gallup surveys. This suggests that while weight loss may improve some health outcomes, it does not immediately reverse the long-term impact of obesity on chronic disease. According to the study authors, once diagnosed, patients remain in the diabetes category regardless of subsequent weight changes, highlighting the complex relationship between obesity and metabolic health.
Access and Attitudes
Public awareness of GLP-1 medications has surged to 89% in 2025, up from 80% the previous year. More than half of Americans view these drugs as helpful for those with obesity or weight-related conditions, although 62% oppose their use for people without such conditions. GLP-1 medications are now covered by Medicaid in 13 states, with ongoing legislative efforts to expand coverage. Former users of GLP-1s report somewhat fewer obesity-related chronic conditions than current users, suggesting modest long-term benefits but not a replacement for healthier daily routines.
Limitations and Considerations
While GLP-1 uptake aligns with reduced obesity rates, the impact on new diabetes incidence remains unproven. The study cautions that GLP-1s should not be considered a cure-all for overall health or other disease states. Non-pharmacologic factors such as physical activity and healthy eating habits remain crucial for sustained health gains. Recent Gallup findings indicate that U.S. adults’ overall health habits have declined compared to 2019, and genetic risk and sociodemographic differences continue to shape the U.S. diabetes and obesity landscapes. Obesity rates are based on self-reported height and weight, which may slightly underestimate true rates due to social desirability, but the trend data are consistent.
Why This Matters
The decline in obesity rates, driven by increased use of GLP-1 medications, marks a potential turning point in the nation’s approach to obesity management. However, the sustainability of these gains will depend on continued access to pharmacotherapy, broader changes in public health behaviors, and ongoing surveillance. This shift could have significant implications for public health policy, healthcare access, and the management of chronic diseases linked to obesity.
